Pre-clinical models of infectious diseases - task area a
Active Awarded Last action
- Contract number
- 75N93024D00017
- Awardee
-
Pharmacology Discovery Services Taiwan, LTD. UEI MXP1NVQ8C1J8
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Task orders
- 3 $1,336,038 obligated
Award facts
- Opportunity
-
- Pre-Clinical Models of Infectious Diseases Pre-Solicitation · NIHAI75N93023R00003 · Posted Oct 21, 2022
- Combined order value
-
- $1,336,038 Current, with exercised options
- $4,818,473 Potential, with all options
- Last date to order 33% complete
- IDV ceiling 1% used
- $146,300,000.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 76 offers Negotiated Proposal / Quote
- Pricing
- Order Dependent (IDV only)
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this IDV
The National Institute of Allergy and Infectious Diseases awarded a single-award indefinite-delivery contract to Pharmacology Discovery Services Taiwan, LTD. on July 15, 2024, with a contract ceiling of $146.3 million and an ultimate completion date of July 14, 2031.
The IDIQ procures preclinical models of infectious diseases, including animal and animal replacement models for screening and evaluating medical countermeasures such as therapeutics, vaccines, and diagnostics. The contract bridges the gap between in vitro testing and clinical evaluation by developing refined preclinical models that assess safety, efficacy, pharmacokinetics, and pharmacodynamics of potential medical interventions. Work emphasizes bacterial infections, urinary tract infections, and models of priority pathogens.
Place of performance is Taiwan, with recent delivery orders directed to Bethesda, Maryland. The originating solicitation was posted on October 21, 2022, with a due date of November 7, 2022.
A delivery order issued on July 15, 2024, under this IDIQ carries a ceiling value of $1,887,190 for murine models of urinary tract infection caused by antibiotic-resistant bacteria and related preclinical infectious disease models, with firm fixed-price pricing and performance in Bethesda, Maryland.
Task orders
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 75N93024D00017?
75N93024D00017 was awarded to Pharmacology Discovery Services Taiwan, LTD. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 15, 2024.
How much is contract 75N93024D00017 worth?
Orders under 75N93024D00017 have obligated $1,336,038. Their combined potential value, with all options, is $4,818,473. 75N93024D00017's own ceiling is $146,300,000.
How many orders have been placed under contract 75N93024D00017?
3 orders have been placed under 75N93024D00017, the latest on September 30, 2026.
Who can order from contract 75N93024D00017?
75N93024D00017 is a single award indefinite delivery contract. Only the awarding agency can place orders on it.
Is contract 75N93024D00017 part of a contract vehicle?
Yes. 75N93024D00017 is part of Pre-Clinical Models of Infectious Diseases.
Was contract 75N93024D00017 competed?
The extent of competition for 75N93024D00017 was full and open competition. The government received 76 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV